ArticleFrontiers in neurology2025
Federated learning for lesion segmentation in multiple sclerosis: a real-world multi-center feasibility study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neurofilament Light Chain (NfL) in Neurodegenerative Diseases: Biological and Clinical Significance, Multi-Omics Integration, and AI-Driven Biomarker Modeling for Precision Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Open neuroinformatics infrastructure ecosystem for federated multisite studies.bioRxiv : the preprint server for biology · 2026Article
- Adaptive multi-stage domain unlearning for white-matter lesion segmentation.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic neuroinflammatory disease driven by immune-mediated central nervous system damage, often leading to progressive disability. Accurate segmentation of MS lesions on MRI is crucial for monitoring disease and treatment efficacy; however, manual segmentation remains time-consuming and prone to variability. While deep learning has advanced automated segmentation, robust performance benefits from large-scale, diverse datasets, yet data pooling is restricted by privacy regulations and clinical performance remains challenged by inter-site heterogeneity. In this proof-of-concept work, we aim to apply and adopt Federated Learning (FL) in a real-world hospital setting. We assessed FL for MS lesion segmentation using the self-configuring nnU-Net model, leveraging 512 MRI cases from three sites without sharing raw patient data. The federated model achieved Dice scores ranging from 0.66 to 0.80 across held-out test sets. While performance varied across sites, reflecting data heterogeneity, the study demonstrates the potential of FL as a scalable and secure paradigm for advancing automated MS analysis in distributed clinical environments. This work supports adopting secure, collaborative AI in neuroimaging, offering utility for privacy-sensitive clinical research and a starting point for medical AI development, bridging the gap between model generalizability and regulatory compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.